目的 探討T細胞共刺激分子及其亞群在胃癌、大腸癌發(fā)生及預后中的作用.方法 應用流式細胞術檢測38例胃癌、42例大腸癌患者和21例健康人(對照組)外周血T細胞亞群及其共刺激分子CD28的表達.結果 T細胞共刺激分子CD28(CD28+CD3+)表達: 胃癌組為(25.80±10.56)%,大腸癌組為(28.95±9.29)%,均明顯高于對照組的(0.82±0.98)%,P＜0.01; 總T細胞(CD3+)表達: 胃癌組為(53.61±13.84)%,大腸癌組為(55.96±10.68)%,均明顯低于對照組的(72.07±7.83)%,P＜0.01; CD4+ T細胞(CD4+CD3+)表達: 胃癌組為(29.84±9.71)%,大腸癌組為(33.75±9.04)%,也均明顯低于對照組的(38.79±5.08)%,P＜0.01, P＜0.05; 細胞毒T細胞(CTL,CD8+CD28+CD3+)表達: 胃癌組為(1.57±1.99)%,大腸癌組為(1.93±2.61)%,均明顯高于對照組的(0.02±0.04)%,P＜0.01; 胃癌組CD8+抑制性T細胞(CD8+CD28-CD3+)和CD4/CD8比值明顯低于對照組[(16.06±6.94)% vs (20.56±6.54)%,P＜0.05; (1.10±0.51)% vs (1.36±0.31)%,P＜0.05]; 大腸癌組調(diào)節(jié)性T細胞(CD4+CD25+CD3+)明顯高于對照組[(19.74±6.89)% vs (13.72±3.08)%, P＜0.01].胃癌組和大腸癌組患者手術前和手術后1周外周血T細胞亞群(除外胃癌組的CD3+細胞和CD28+CD3-細胞)的差異無統(tǒng)計學意義(P＞0.05). 結論胃癌和大腸癌患者T細胞數(shù)量明顯減少,T細胞共刺激分子CD28表達增高.胃癌患者CD4+T細胞顯著減少; 大腸癌患者調(diào)節(jié)性T細胞顯著增加.
引用本文： 傅冷西,張聲,陳思曾. T 細胞共刺激分子及其亞群在胃癌和大腸癌組織中表達的意義. 中國普外基礎與臨床雜志, 2008, 15(1): 51-55. doi: 復制
| 1. | Antony PA,Piccirillo CA,Akpinarli A,et al.CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells[J].J Immunol,2005; 174(5)∶2591. |
| 2. | 林學顏,張玲主編.現(xiàn)代細胞分子免疫學[M].第1版.北京:科學出版社,2003∶384～385. |
| 3. | Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995; 155(3)∶1151. |
| 4. | Chattopadhyay S,Chakraborty NG,Mukherji B.Regulatory T cells and tumor immunity[J].Cancer Immunol Immunother,2005; 54(12)∶1153. |
| 5. | 吳靜靜,王俐.CD4+CD25+ 調(diào)節(jié)性T 細胞及其與腫瘤的關系[J].國外醫(yī)學·腫瘤學分冊,2004; 31(7)∶496. |
| 6. | 李曉,汪輝.CD4+CD25+調(diào)節(jié)性T細胞和腫瘤免疫[J].國外醫(yī)學·免疫學分冊,2003; 26(6)∶326. |
| 7. | Yu P,Lee Y,Liu W,et al.Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors[J].J Exp Med,2005; 201(5)∶779. |
| 8. | Seo N,Hayakawa S,Takigawa M,et al.Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity[J].Immunology,2001; 103(4)∶449. |
| 9. | 劉莉,丁乾,姚軍霞,等.結直腸癌患者外周血CD4+CD25high調(diào)節(jié)性T細胞分析[J].中華腫瘤防治雜志,2007; 14(2)∶110. |
| 10. | 任秀紅,劉莉,劉平平,等.惡性腫瘤患者T細胞亞群變化及其與腫瘤分期的關系[J].第三軍醫(yī)大學學報,2006; 28(18)∶1906. |
| 11. | Ercolini AM,Ladle BH,Manning EA,et al.Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response[J].J Exp Med,2005; 201(10)∶1591. |
| 12. | Sasada T,Kimura M,Yoshida Y,et al.CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression[J].Cancer,2003; 98(5)∶1089. |
| 13. | Scotto L,Naiyer AJ,Galluzzo S,et al.Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28-T suppressor cells[J].Hum Immunol,2004; 65(11)∶1297. |
| 14. | 金伯泉主編.細胞和分子免疫學[M].第2版.北京:科學出版社,2001∶17. |
| 15. | 林文棠,朱平主編.實用臨床免疫學[M].第1版.西安:第四軍醫(yī)大學出版社,2003∶166～168. |
| 16. | 李曉,徐蘭波.共刺激分子在腫瘤免疫治療中的應用[J].國外醫(yī)學·腫瘤學分冊,2005; 32(1)∶25. |
| 17. | 張曉膺,鄭世營,趙軍,等.外源性B7-1基因誘導抗肺癌主動免疫的實驗研究[J].中華實驗外科雜志,2005; 22(7)∶884. |
| 18. | 張清媛,李殿俊,王志華,等.B7-1基因修飾的腫瘤細胞疫苗抗腫瘤的實驗研究[J].中國免疫學雜志,2001; 17(5)∶249. |
| 19. | 陳農(nóng).胃癌患者手術前后外周血自然殺傷細胞和T淋巴細胞亞群的變化[J].浙江醫(yī)學,2002; 24(10)∶579. |
| 20. | 董暉,王朝杰.結直腸癌患者免疫狀況與腫瘤分期的關系[J].國外醫(yī)學·放射醫(yī)學核醫(yī)學分冊,2005; 29(3)∶115. |
| 21. | 陳榮,蔡景理,周斌,等.免疫增強型腸內(nèi)營養(yǎng)制劑對結直腸腫瘤術后機體免疫的影響[J].中華胃腸外科雜志,2005; 8(4)∶328. |
- 1. Antony PA,Piccirillo CA,Akpinarli A,et al.CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells[J].J Immunol,2005; 174(5)∶2591.
- 2. 林學顏,張玲主編.現(xiàn)代細胞分子免疫學[M].第1版.北京:科學出版社,2003∶384～385.
- 3. Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995; 155(3)∶1151.
- 4. Chattopadhyay S,Chakraborty NG,Mukherji B.Regulatory T cells and tumor immunity[J].Cancer Immunol Immunother,2005; 54(12)∶1153.
- 5. 吳靜靜,王俐.CD4+CD25+ 調(diào)節(jié)性T 細胞及其與腫瘤的關系[J].國外醫(yī)學·腫瘤學分冊,2004; 31(7)∶496.
- 6. 李曉,汪輝.CD4+CD25+調(diào)節(jié)性T細胞和腫瘤免疫[J].國外醫(yī)學·免疫學分冊,2003; 26(6)∶326.
- 7. Yu P,Lee Y,Liu W,et al.Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors[J].J Exp Med,2005; 201(5)∶779.
- 8. Seo N,Hayakawa S,Takigawa M,et al.Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity[J].Immunology,2001; 103(4)∶449.
- 9. 劉莉,丁乾,姚軍霞,等.結直腸癌患者外周血CD4+CD25high調(diào)節(jié)性T細胞分析[J].中華腫瘤防治雜志,2007; 14(2)∶110.
- 10. 任秀紅,劉莉,劉平平,等.惡性腫瘤患者T細胞亞群變化及其與腫瘤分期的關系[J].第三軍醫(yī)大學學報,2006; 28(18)∶1906.
- 11. Ercolini AM,Ladle BH,Manning EA,et al.Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response[J].J Exp Med,2005; 201(10)∶1591.
- 12. Sasada T,Kimura M,Yoshida Y,et al.CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression[J].Cancer,2003; 98(5)∶1089.
- 13. Scotto L,Naiyer AJ,Galluzzo S,et al.Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28-T suppressor cells[J].Hum Immunol,2004; 65(11)∶1297.
- 14. 金伯泉主編.細胞和分子免疫學[M].第2版.北京:科學出版社,2001∶17.
- 15. 林文棠,朱平主編.實用臨床免疫學[M].第1版.西安:第四軍醫(yī)大學出版社,2003∶166～168.
- 16. 李曉,徐蘭波.共刺激分子在腫瘤免疫治療中的應用[J].國外醫(yī)學·腫瘤學分冊,2005; 32(1)∶25.
- 17. 張曉膺,鄭世營,趙軍,等.外源性B7-1基因誘導抗肺癌主動免疫的實驗研究[J].中華實驗外科雜志,2005; 22(7)∶884.
- 18. 張清媛,李殿俊,王志華,等.B7-1基因修飾的腫瘤細胞疫苗抗腫瘤的實驗研究[J].中國免疫學雜志,2001; 17(5)∶249.
- 19. 陳農(nóng).胃癌患者手術前后外周血自然殺傷細胞和T淋巴細胞亞群的變化[J].浙江醫(yī)學,2002; 24(10)∶579.
- 20. 董暉,王朝杰.結直腸癌患者免疫狀況與腫瘤分期的關系[J].國外醫(yī)學·放射醫(yī)學核醫(yī)學分冊,2005; 29(3)∶115.
- 21. 陳榮,蔡景理,周斌,等.免疫增強型腸內(nèi)營養(yǎng)制劑對結直腸腫瘤術后機體免疫的影響[J].中華胃腸外科雜志,2005; 8(4)∶328.